The handle http://hdl.handle.net/1887/28735 holds various files of this Leiden University dissertation

**Author:** Zeestraten, Eliane  
**Title:** Clinical application of biomarkers in colon cancer: studies on apoptosis, proliferation and the immune system  
**Issue Date:** 2014-09-17
CHAPTER 2

The prognostic value of the apoptosis pathway in colorectal cancer: A review of the literature on biomarkers identified by immunohistochemistry

E. Zeestraten, A. Benard, M. Reimers, P. Schouten, G. Liefers, C. van de Velde, P. Kuppen.

Biomarkers in cancer. 2013: 5 13-29
ABSTRACT

Research towards biomarkers that predict patient outcome in colorectal cancer (CRC) is rapidly expanding. However, none of these biomarkers have been recommended by the American Association of Clinical Oncology or the European Group on Tumor Markers. Current staging criteria result in substantial under- and over-treatment of CRC patients. Evasion of apoptosis, a characteristic feature of tumorigenesis, is known to correlate with patient outcome. We reviewed the literature on immunohistochemistry-based studies between 1998 and 2011 describing biomarkers in this pathway in CRC and identifying 26 markers. Most frequently described were p53, Bcl-2, survivin and the Fas and TRAILRI receptors and their ligands. None of the studies reviewed provided sufficient evidence for implementing a single marker into current clinical practice. This is likely due to the complex biology of this pathway. We suggest focusing on the combination of key markers within the apoptosis pathway that together represent an ‘apoptotic tumor profile’, which better reflects the status of this pathway in a tumor.
INTRODUCTION

Colorectal cancer (CRC) is currently one of the major contributors to cancer-related deaths worldwide (1;2). The amount of data emerging from studies aimed at optimizing the diagnostic process and treatment of this disease is rapidly increasing. This makes the process of tumor development in CRC one of the most thoroughly studied and best characterized models of tumorigenesis. By emphasizing the need of early detection and development of new and improved treatment regimens, an increased understanding of the disease did lead to decreased mortality rates of nearly 5 percent over the last decade (3-10). However, CRC-related morbidity and mortality affects approximately 800,000 individuals each year worldwide (2). The survival of CRC patients largely depends on disease stage at the time of diagnosis and varies widely between the stages. In clinical practice, however, treatment allocation and outcome prediction is still solely based on the International Union Against Cancer (UICC) Tissue Node Metastasis (TNM) classification (11). Addition of several pathology-based tumor characteristics is currently used to identify high-risk stage II patients that may benefit from adjuvant chemotherapy. These include perforation of the bowel wall at presentation, tumor invasion at the T4 level, venous tumor invasion, lymph node yield less than 10, and poor or no differentiation of the tumor cells (12). There is substantial evidence that even with the addition of these risk factors of poor outcome, TNM classification falls short in daily practice and may cause over- or, even worse, under-treatment of patients (11;13-15;15-18).

In an attempt to improve treatment outcomes for CRC patients, both the American Society of Clinical Oncology’s Tumor Markers Expert Panel (ASCO TEMP-2006) and its European counterpart; The European Group on Tumor Markers (EGTM-2007) have reviewed the available literature to determine the clinical applicability of a number of widely studied biomarkers (19-21). Their conclusions were clear and consistent: despite the overwhelming amount of literature, no biomarkers have been recommended for clinical use. Therefore, to improve current staging criteria, new biomarkers must be identified and validated for clinical use. Pepe et al. have developed a five-step program that can be used for the development of new biomarkers (22). The first step is biomarker discovery in a preclinical, exploratory setting. Subsequently, the clinical value of these biomarkers must be determined and verified in a large retrospective study. Those results then need to be the validated and eventually confirmed by a prospective randomized controlled trial. It is not until these steps are completed successfully that biomarkers are ready for introduction into clinical practice. The first step which involves identifying or discovering new biomarkers, can be accomplished by studying the process of tumorigenesis and its related pathways. Cancer cells harbor at least six features that distinguish them from normal cells, one of which is the characteristic ability to evade programmed cell death or apoptosis (23). In normal tissues apoptosis plays a pivotal role in the maintenance of tissue homeostasis and the development of the immune
system (24;25). Disturbance of this process in tumor cells results in the impaired removal of mutated cells and contributes to tumor progression. In addition, evasion of apoptosis enables malignant cells to escape from tumor immune surveillance and to acquire resistance to cancer therapy. In previous retrospective studies, the status of the apoptotic pathway in a tumor was shown to be of prognostic value in colorectal cancer patients (26-37). Therefore, we focused on this pathway in our search for new potential prognostic biomarkers in colorectal cancer. In this review, we provide an overview of studies designed to determine the prognostic value of biomarkers within the apoptotic pathway in colorectal cancer. Furthermore, we will discuss some of the difficulties and controversies that can arise when studying this tightly regulated and complex process. The goal is to identify key biomarkers in the apoptotic pathway that may be used clinically to determine cancer prognosis. We first discuss the route of apoptosis to identify the key proteins in this process and then link this information to studies that examined the prognostic value of these proteins in colorectal cancer. Since immunohistochemistry (IHC) is still the most widely applied and available technique in pathology to determine the expression status of tumor-associated proteins and to study the clinical prognostic relevance of biomarkers, we limited our search to IHC studies.

**DATA COLLECTION AND ANALYSIS**

In order to review the literature on prognostic biomarkers related to the pathway of apoptosis, determined using IHC in CRC patients, we performed a search of the Pubmed, Embase and Web of Science databases. We used broad search terms, as recommended in the Stroup guidelines (38), to identify publications of interest published between January 1998 and June 2011. Key search terms included colorectal cancer, biomarker, apoptosis, prognosis, and immunohistochemistry. The following search strategy (simplified) shows how some of these terms were combined in our Web of Science Search; “TS=((colorectal or colon or colonic or rectal or rectum) SAME (neoplasm or cancer or tumor or carcinoma)) AND TS=((prognostic or tumor or cancer or neoplasm or biological or intracellular or signaling or intracellular signaling) SAME (marker or protein or peptide)) AND TS=((prognosis or prognostic or morbidity or mortality or recurrence or relapse or (disease SAME progression))) AND TS=(immunohistochemistry or immunolabeling or immunocytohistochemistry). After amalgamating the results from the three medical databases and discarding the duplicates, this strategy yielded a total of 2923 unique citations. To extract papers for review, we screened the results for title and abstract. We used the following criteria to determine whether a study was considered eligible for the review:

a) The study contained data on a marker directly involved in the pathway of apoptosis;
b) The study was performed in primary tumors from CRC patients;
c) The study was performed using IHC;
d) The study contained an analysis of the relationship between expression of the marker and clinical outcome. We selected only studies that used logistic regression or survival curve-based statistical analysis methods to evaluate the impact of a marker;  
e) A full publication in English with details of the method used was available.

RESULTS

Overall, we were able to indentify 26 potentially prognostic biomarkers that are directly involved in the apoptotic pathway, which will be discussed in detail below (figure 1). These markers were all studied using IHC in the 124 eligible publications that remained after applying our selection criteria from the total of 2923 publications. Expression patterns of these apoptotic (bio)markers were related to patient outcome using logistic regression or survival curve-based analysis methods. Most of the papers, over 800, were excluded because they described the expression of markers related to the pathway of apoptosis in other types of cancers than colorectal cancer, despite the fact that our search terms included colorectal cancer as a major search term. Over 900 citations were excluded because they did not describe the marker in primary colorectal cancer lesions but rather in metastatic lesions. Table 1 provides an overview of our selection criteria and the corresponding number of citations that were excluded based on these criteria.  
The general pathway of apoptosis is illustrated in figure 1 and includes the markers that discussed in this review. Although this figure represents a simplified version of the pathway, it shows that the process of apoptosis is highly regulated at multiple levels. Based on the stimuli presented, two pathways initiating the apoptotic process can be identified (39). The extrinsic pathway is triggered by external death signals that cause the formation of intracellular signaling complexes at the death receptors. This type of apoptosis is usually activated in immune responses (40). The second pathway, known as the intrinsic pathway, is activated by many different stimuli, including growth factor deprivation and DNA damage, caused by factors such as UV or gamma-irradiation or by chemotherapeutic agents. Exposure of cells to these stimuli initiates a set of intracellular death signals mediated by the p53 protein that activates the apoptotic process. Mitochondria play an important role in the intrinsic pathway with a major regulatory role for the Bcl-2 family members. Although already intimately connected via caspase-8 and Bid, both pathways converge at the level of the caspase-cascade that eventually leads up to the proteolytic activation of the executioner members such as caspase-3 (41). The function of the caspase proteins is again highly regulated by a group of so-called inhibitor of apoptosis proteins (IAPs) (42). In general, executioner caspses will cleave several substrates, thus acting as a cellular disassembly machine. Cleavage of these substrates is eventually responsible for the morphological features that hallmark apoptotic cell death including membrane blebbing, cell shrinkage and chromatin condensation (26;41).
To discuss the results of our literature review in an orderly fashion, markers are grouped and discussed based on their location in the pathway as described in figure 1, starting with the extrinsic pathway of apoptosis and ending with the IAPs. In addition, table 2 provides a general overview of the number of studies identified that describe the prognostic value of a particular marker, grouped by their function and location in the pathway of apoptosis in the order at which they will be discussed in this review.

**The Death Receptor Family and the extrinsic pathway of apoptosis**

The most studied signaling pathway in apoptosis is the extrinsic pathway, activation of which is primarily facilitated by the death receptors (DRs). Based on our search we were able to identify 8 individual biomarkers in this part of the apoptotic
Table 1 provides an overview of the exclusion criteria that were used to select the most relevant citations. The criteria were applied to the 2923 citations retrieved in our search of literature in three major online medical databases. The material and methods section provides further background on the postulation of these criteria and outline of our literature search.

The number of citations excluded from further analyses based on each criterion is listed. Based on the criteria A, B, C, D, and E, 2799 citations were excluded from the selection. Therefore, 124 citations remained for in depth review of the prognostic value of the markers studied.

Table 1
Selection of relevant studies on clinical prognosis of apoptosis-related markers

| Exclusion Criteria                                                  | Number of citations excluded |
|---------------------------------------------------------------------|------------------------------|
| A. The study describes data on a marker not directly involved in apoptosis | 642                          |
| B. The study was not performed in primary colorectal cancer patients | 985                          |
| C. The study was not performed using immunohistochemistry           | 707                          |
| D. The study did not contain validated outcome results              | 315                          |
| E. An English full text version was not available                   | 150                          |
| Total number of citations excluded based on these exclusion criteria | 2799                         |
| Total number of citations included (2923-2799)                      | 124                          |

Table 1 provides an overview of the exclusion criteria that were used to select the most relevant citations. The criteria were applied to the 2923 citations retrieved in our search of literature in three major online medical databases. The material and methods section provides further background on the postulation of these criteria and outline of our literature search.

The number of citations excluded from further analyses based on each criterion is listed. Based on the criteria A, B, C, D, and E, 2799 citations were excluded from the selection. Therefore, 124 citations remained for in depth review of the prognostic value of the markers studied.

pathway of which the prognostic relevance was studied in CRC patients. These markers included: Fas receptor (FasR), TRAIL1, TRAILR2, TRAILR3, TRAILR4, FasL, TRAIL, and c-Flip (table 2). A unique feature of the extrinsic pathway is that DRs can induce apoptosis independently of the p53 tumor suppressor gene. DRs are members of the tumor necrosis factor receptor superfamily, of which eight family members have been characterized (43;44). The most common receptors are FasR (CD95, DR2) with its ligand FasL and TRAILR1 and -R2 (DR4 and DR5) with their ligand TRAIL (Tumor necrosis factor (TNF)-Related Apoptosis-Inducing Ligand). All DRs contain cysteine-rich extracellular domains that allow them to recognize their ligands with great specificity. They also harbor intracellular sub-domains better known as the Death Domains (DDs) (45). DDs allow them to interact with adapter molecules such as FADD (Fas-associated Death Domain) (46). Signal transduction within the extrinsic pathway starts with the binding of the ligands to the DRs, followed by the formation of multi-protein signaling complexes called death inducing signaling complexes (DISCs) at the intracellular domains of the DRs (47;48). The DISC complex auto-activates pro-caspase 8 through interaction with a FADD protein. Activated caspase-8 will eventually activate the effector caspase-3 by proteolytic cleavage (48-51). Downregulation of any of the DRs or downstream apoptotic proteins might cause severe limitations in the induction of apoptosis through the extrinsic pathway. There are two other mechanisms involved in the regulation of the extrinsic signaling pathway. First, TRAIL can also bind to two decoy receptors (DcR) in addition to the DRs, including DcR1 and DcR2 (also known as TRAILR3 and TRAILR4, respectively). However, neither decoy receptors can transduce an apoptosis-stimulating signal upon TRAIL binding. The sensitivity of a cell to TRAIL-
Table 2
Overview of markers of the apoptosis pathway

| Marker      | Function in the pathway                  | Number of studies | References                              |
|-------------|------------------------------------------|-------------------|-----------------------------------------|
| **Intrinsic pathway** |                                          |                   |                                         |
| P53         | Triggers the intrinsic pathway           | 31                | (31;71;73-76;76;90;113;113-136)*         |
| Bcl-2       | Anti-apoptotic Bcl-2 family member       | 38                | (29;31;35;73;83-90;94;113;114;116;118;123;125;128;129;132;134;137-151) |
| Bcl-XL      | Anti-apoptotic Bcl-2 family member       | 1                 | (90)                                    |
| Bag1        | Enhancing anti-apoptotic function of Bcl-2| 2                 | (90;151)                                |
| Apaf-1      | Formation of the apoptosome             | 8                 | (90;113;118;121;152-155)                |
| Bax         | Pro-apoptotic Bcl-2 family member       | 8                 | (90;123;123;146;147;156-159)            |
| Bad         | Pro-apoptotic Bcl-2 family member       | 1                 | (160)                                   |
| Bid         | Pro-apoptotic Bcl-2 family member       | 2                 | (90;160)                                |
| Bim         | Pro-apoptotic Bcl-2 family member       | 1                 | (161)                                   |
| Noxa        | Pro-apoptotic Bcl-2 family member       | 1                 | (161)                                   |
| Puma        | Pro-apoptotic Bcl-2 family member       | 1                 | (161)                                   |
| Caspase-8   | Initiator Caspase of intrinsic pathway  | 2                 | (60;155)                                |
| **Extrinsic pathway** |                                          |                   |                                         |
| FasR        | Death receptor                          | 2                 | (56;57)                                 |
| TrailR1     | Death receptor                          | 2                 | (57;59)                                 |
| TrailR2     | Death receptor                          | 2                 | (57;59)                                 |
| DcR1        | Decoy death receptor                    | 1                 | (57)                                    |
| DcR2        | Decoy death receptor                    | 1                 | (57)                                    |
| FasL        | Death receptor ligand                   | 1                 | (56)                                    |
| TRAIL       | Death receptor ligand                   | 3                 | (57;59;60)                              |
| c-Flip      | Inhibitor of extrinsic apoptosis induction| 2                 | (56;60)                                 |
| Caspase 9   | Initiator Caspase of the extrinsic pathway| 1                 | (155)                                   |
| **Cascade regulator** |                                         |                   |                                         |
| IAP         | Inhibitor of the Caspase cascade        | 3                 | (90;162;163)                            |
| Survivin    | Inhibitor of the Caspase cascade        | 8                 | (35;90;94-97;99;108)                    |
| Tucan       | Inhibitor of the Caspase cascade        | 1                 | (90)                                    |
| XIAP        | Inhibitor of the Caspase cascade        | 2                 | (90;164)                                |
| Smac/Diablo | Inhibitor of the IAP’s, pro-apoptotic   | 3                 | (90;163;165)                            |

Listed are biomarkers related to the pathway of apoptosis that emerged from the review of the literature. The biomarkers were studied by immunohistochemical analyses and their expression was related to clinical outcome in colorectal cancer patients. For each marker, the number of publications in which these markers were studied and their primary function within the pathway of apoptosis are listed.

* The systematic review of Munro et al., in which the available literature on the prognostic value of p53 expression until 2005 was reviewed extensively, was used as a starting point for our search in of the IHC literature on p53 expression. We therefore only included studies published since this review.
mediated apoptosis may, therefore, be a function of the ratio of DcR to DR. If there is significant upregulation of the DcRs or downregulation of the DRs, TRAIL will bind to the DcRs instead of the DRs, and the apoptotic signaling is interrupted (52). Secondly, cellular Flice-Like Inhibitory Protein (c-FLIP) is, similarly to FADD, a DD-containing protein and can competitively bind to FADD in the DISC formation process instead of the DD domain of the DRs (figure 1). This protein, particularly in the c-FLIP_L isoform, shows strong structural similarities to pro-caspase-8, and might be a potentially strong inhibitor of the extrinsic apoptotic pathway. There are two other features that are unique to the extrinsic pathway, but contribute considerably to the complexity of its regulation. The first feature is an indirect link with the intrinsic pathway, which can be activated through the formation of tBid, a truncated form of the BID protein. In a subset of cells known as type II cells, DISC formation occurs less frequent, resulting in less caspase-8 activation and subsequently truncation of the Bid protein into tBid (53). tBid induces oligomerization of Bax or Bad, upon which the mitochondria release cytochrome c, and this eventually induces apoptosis further down the intrinsic pathway. Because of the mitochondrial involvement, the regulation of apoptosis in Type II cells is subject to regulation by the Bcl-2 family proteins. This regulation, which will be discussed in detail in this review, provides the cell with an apoptosis-evading mechanism such as downregulation of DR expression that may occur in a cell during tumorigenesis (54). A second feature unique to the extrinsic pathway is explained by the so-called ‘Fas-Counterattack hypothesis’ (55). In normal tissue homeostasis, the Fas/FasL-induced extrinsic pathway of apoptosis plays a major role in immune surveillance. Activated T lymphocytes express FasL and upon recognition of a tumor cell as a target (via MHC-presented peptides on the tumor cell surface), a tumor cell expressing the FasR may be eliminated by induction of apoptosis. However, it is known that tumor cells can also express FasL and thus are able to counterattack cells from the immune system (55). By downregulation of FasR expression as well as by upregulation of FasL expression, tumor cells can escape immune surveillance. In summary, the key players of the extrinsic pathway are the DRs, specifically TRAILR1, R2 and FasR and their ligands. The way tumor cells try to disrupt signaling through these DRs to overcome apoptosis has been widely studied in many types of cancers. Our search identified 12 studies in which one or more of these DRs and their ligands were studied. In 5 of the 12 studies, one of the DR pathway-related markers (FasR, FasL, TRAILR1 and TRAIL) was found to be of significant prognostic value (56-60) (table 3). Hypothetically, based on the biology of the process of tumorigenesis, downregulation of expression of the DRs or upregulation of expression of their ligands would indicate a more aggressive tumor type, and hence worse clinical outcome parameters. Interestingly, most studies reported that upregulation of the expression of Fas and TRAIL was significantly related to worse outcome parameters. The expression of FasL and FasR was studied by both Korkolopoulou et al. and Strater et al. (56;58). In the smaller study by Korkolopoulou et al. involving 90 patients, normal cells did not express FasL, but tumor cells showed significant upregulation, which was related to a significantly lower overall
Table 3
Extrinsic pathway of apoptosis

| Marker   | Reference | Population size | Tumor Type | Disease Stage | Expression | Outcome parameter | Hazard Ratio | p-value |
|----------|-----------|-----------------|------------|---------------|------------|-------------------|--------------|---------|
| FasR     | Strater(58)| 128             | Colon      | II-III        | Up         | DFS               | 0.4          | 0.034   |
| FasL     | Korkolopoulou(56)| 90             | Colon      | I-IV          | Up         | OS                | 3.491        | 0.005   |
| TRAILR1  | Van Geelen(59)| 376            | Colorectal | III           | Up         | REC               | 2.19         | 0.03    |
|          | Strater(57) | 129             | Colon      | II-III        | Up         | OS                | 2.22         | 0.04    |
| TRAIL    | McLornan(60)| 253             | Colorectal | II-III        | Up         | OS                | 1.210        | 0.026   |

Abbreviations: DFS (Disease Free Survival), OS (Overall Survival), REC (Recurrence), Up (Upregulation of the expression of the marker). This table provides the references of the studies that describe the prognostic value of FasR, FasL, TRAILR1, or TRAIL, identified in this review. For each marker the important study characteristics are listed.

Survival (OS) (56). Tumor cells also showed expression of the Fas receptor with a mainly cytoplasmatic and granular staining pattern. According to the authors, this indicates that although Fas receptor was present, it had no true functional properties. Therefore, according to the authors, the seemingly contradictory result of a worse outcome despite upregulation of the DR expression could be explained by the Fas-Counterattack hypothesis. In the second study by Strater et al., overexpression of Fas receptor correlated with a significantly better disease free survival (DFS) (58). Unfortunately, this study did not describe the exact location of FasR expression in the cell. Therefore, it is difficult to determine whether their results confirm Korkolopoulou results or actually oppose them. We were therefore not able to determine whether the Fas-Counterattack hypothesis has true clinical value in CRC.

With respect to DR4 and its ligand TRAIL we could identify three studies reporting on the prognostic value of these biomarkers in CRC (57;59;60). In all studies, upregulation of expression of DR4 or its ligand were related to worse outcome parameters such as higher levels of recurrence and shorter OS. This apparent contradiction with expectations based on biology of tumorigenesis can, according to Van Geelen et al., be explained by the fact that DR4 is also known to have effects on cell proliferation through the activation of nuclear factor kappa B (NF-κB), as described in a number of studies (60-63).

In conclusion, we were able to identify five studies that report on FasL, FasR, TrailR1, or TRAIL 2 as significant prognostic markers in colorectal cancer patients. Conclusions varied, which might be due to differences in patient selection and/or study methods. However, more importantly, their conclusions were in contradiction with what is expected based on the biology of the apoptosis pathway. This can be explained by the fact that the functionality of this extrinsic part of the apoptotic pathway in the included studies was only investigated using changes in protein expression patterns of the tumor cells. The involvement of the immune system...
was not considered in the majority of these studies. The process of tumorigenesis attracts many cells that are part of the immune system into the tumor microenvironment. The presence of these cells such as activated CD8+ T cells or Foxp3+ regulatory T cells has been shown to be of prognostic relevance in CRC (64;65). Moreover, activated T cells produce CD95 ligand and can hereby trigger apoptosis in target cells such as tumor cells (66). As described above, some tumors cells might be able to counteract this mechanism and remove attacking antitumor T cells by increasing their own CD95L expression. However, this counterattack theory has not yet been conclusively demonstrated in vivo. Therefore, until additional preclinical, exploratory research has been performed to clarify how the pathway of apoptosis and the immune system interact, none of the related markers appear suitable for clinical prognostic application.

P53 tumor suppressor gene and the intrinsic pathway of apoptosis
The p53 tumor suppressor gene, likely the most well known protein within the intrinsic pathways of apoptosis, encodes for a transcription factor that regulates the expression of genes involved in the pathway of apoptosis, as well as angiogenesis, cell cycle progression and genomic maintenance (67;67;68). Within the intrinsic pathway it exerts its function at the beginning of the intrinsic apoptotic pathway. It causes the cell cycle to arrest at the G1 phase in response to DNA damage; in case the DNA damage turns out to be irreparable, the p53 protein will activate the appropriate cellular signaling cascades to execute apoptosis. In 50% of human colorectal cancers p53 is absent or mutated, which has major implications for the execution of apoptosis in colorectal cancer (69). Mutations in p53 can be determined using IHC because mutated proteins accumulate in the nucleus due to their increased half-life (70). Different mutations have different effects and can implicate either loss or gain of function of the p53 protein. Two research groups carried out major systematic reviews on the relationship between p53 abnormalities and outcome in colorectal cancer patients (71;72). Munro et al reviewed a total of 168 IHC-based studies as well as mutation-based studies (71). Russo et al. pooled data from studies analyzing p53 DNA mutations only (72). Together, these studies reported on p53 expression and mutations in relation to survival in 18,766 patients. Their key finding was that abnormal expression of p53, detected using IHC, was related to an increased risk of death. They concluded that mutations in exon 5 were associated with an adverse outcome, predominantly in proximal, right-sided tumors. Both studies suggested an impact of mutated p53 on clinical outcome, though this relationship was only modest despite the overwhelming amount of data analyzed. The results of these studies were taken into account in the review of prognostic biomarkers in CRC by the ASCO Clinical Oncology’s Tumor Marker Expert Panel in 2006. The ASCO panel’s recommendation was that with current methods of detection, using either mutation analysis or IHC, p53 status was a poor guide for prediction of prognosis in colorectal cancer patients (19). Since the published literature on IHC-based p53 studies until 2005 has already been thoroughly reviewed by Munro et al., we limited our search to reports that
Table 4
P53 as a clinical prognostic marker

Overview of the literature on p53 expression in which p53 was proven to be an independent prognostic indicator of outcome in CRC patients

| Reference  | Population size | Tumor Type   | Disease Stage | Outcome parameter | Hazard Ratio | p-value |
|------------|-----------------|--------------|---------------|-------------------|--------------|---------|
| Noske(76)  | 116             | Colorectal   | III           | OS                | -            | 0.048   |
| Munro* (71)| 12257           | Colorectal   | I-IV          | OS                | 1.32         | <0.0001 |
| Torsello(73)| 58              | Colorectal   | I-IV          | OS                | 2.48         | 0.046   |
|            | (<40 years age) |              |               |                   |              |         |
| Lim(75)    | 213             | Colorectal   | I-III         | OS                | 1.843        | 0.028   |
| Jurach(74) | 83              | Rectal       | II-III        | OS                | 2.32         | 0.01    |
|            |                 |              |               | DFS               | 2.45         | 0.04    |

Abbreviations: OS (Overall Survival), DFS (Disease Free Survival).

This table provides the references of all the studies that were identified in this review to report on upregulation of p53 expression as a statistically significant, independent predictor of outcome in CRC patients.

*This article describes a review of multiple studies on the prognostic value of upregulated p53 expression determined with immunohistochemistry (IHC) in colorectal cancer patients.

have been published since. We identified an additional 30 studies reporting on the expression of p53 determined with IHC that were published after Munro’s review in 2005. Four of these 30 papers confirmed the results of Munro et al. and claimed p53 to be a significant, prognostic marker in colorectal cancer (73-76). Table 4 provides an overview of their study characteristics. From this table, it can be concluded that although p53 has been widely studied, the studies reporting on statistically significant prognostic relevance show differences in population size, tumor type selection, and disease stage selection. When we examined these publications in more detail, we also noticed that they varied in their IHC methods. Previously, a comparative study by Baas et al. has demonstrated the monoclonal antibody DO7 to be superior over 5 other antibodies in the detection of the p53 gene protein in archival tissue of colorectal carcinomas (77), suggesting that this antibody should be used as a gold standard for IHC of p53. This particular antibody was used in 3 out of the 4 studies listed (73,75,76). Furthermore, the sample sizes of all studies were rather small at an average of 103 patients; and a closer look at these populations showed that most also seemed highly selected on clinical parameters. For example, Jurach et al. only included stage II and III rectal cancer patients and the small cohort of Torsello et al. consisted only of patients under age 40 (73,74). The only relatively large study by Lim et al. that analyzed the results of 231 stage I, II and III CRC patients, showed a correlation between upregulation of p53 expression and poor OS (75). This correlation was more pronounced in their stage III patient selection, but disappeared when only the adjuvant-treated patients were analyzed. Their results appeared to be confirmed by the study of Noske et al. (76). However, in this study the prognostic value of p53 was only present in a multivariate analysis when expression was analyzed in combination with p21 expression, a major
downstream cell cycle inhibitor. The expression of p53 alone in univariate analysis was only borderline significant at a p-value of 0.045 in this cohort of 116 stage II/III patients. As a single marker, p53 expression showed no independent statistical significance with respect to the prediction of outcome. Hence, neither of the four studies, although they claimed p53 to be an independent prognostic predictor of outcome in CRC, were able to add more significance to the conclusions drawn by Munro et al. (71). Therefore, their results are likely not sufficiently significant to alter the recommendations of the ASCO of 2006 with respect to the applicability of p53 as a prognostic biomarker in colorectal cancer (19).

The Bcl-2 family members and the intrinsic apoptotic pathway

Downstream of p53, the mitochondria play a major role in the initiation and execution of the intrinsic pathway of apoptosis. The B-cell CLL/Lymphoma 2 (BCL-2) family members are mainly responsible for regulating the intrinsic pathway and can be categorized into two groups. The first group consists of anti-apoptotic proteins that are structural and functional homologs of Bcl-2. The most important members of this group are Bcl-2 itself and its splice variant Bcl-2 XL (78;79). They are mainly bound to the mitochondrial outer membrane (MOM) by their transmembrane (TM) domain, where they stabilize the MOM to prevent cytochrome c release into the cytosol of the cell under normal homeostatic circumstances (80). Therefore, they can be considered anti-apoptotic proteins (81).

The second group of Bcl-2 family members has pro-apoptotic capacities. These members include Bcl-2 associated X protein (BAX) and proteins such as Bad, Bid, Bim, Bik, Noxa and Puma, which are, based on their structure, also known as BH3-only proteins (78). These proteins are usually bound to the cytoskeleton or cytosol, but upon stimulation they interact with and inhibit their anti-apoptotic counterparts such as Bcl-2 (78). The relative ratio or balance between the expression of both groups of Bcl-2 family members will determine whether stimulation of the intrinsic pathway of apoptosis results in apoptosis as is graphically pointed out in Figure 1. If the pro-apoptotic factors predominate, cytochrome c will be released into the cytosol where it binds to the apoptosis-activating factor 1 (Apaf-1) to form an apoptosome. More downstream in the apoptotic pathway, this apoptosome will form a complex together with an initiator caspase, caspase-9. This caspase will subsequently activate the executioner caspases, caspase-3 and -7 (78;82). Deregulation of apoptosis during tumor development can be caused by a disturbance in the homeostatic balance of the Bcl-2 family members.

Our search resulted in 55 studies describing the prognostic relevance of markers related to the Bcl-2 protein family. In the majority of these studies, 38 in total, the expression of Bcl-2 was studied using IHC. In only 9 out of these 38 studies a statistically proven prognostic relevance of this marker could be established (table 5) (73;83-90). The 9 studies generally used the same methods to determine Bcl-2 expression and all but one were performed on whole paraffin-embedded tissue sections. Furthermore, they were very consistent in their conclusions: in all studies upregulation of Bcl-2 was related with better survival, as shown for either
### Table 5

**Bcl-2 as a clinical prognostic marker**

Overview of the studies reporting on Bcl-2 as significant, prognostic marker within the pathway of apoptosis.

| Reference          | Population size | Tumor Type | Disease Stage | Expression | Outcome parameter | Hazard Ratio | p-value   |
|--------------------|-----------------|------------|---------------|------------|-------------------|--------------|-----------|
| Buglioni (83)      | 171             | Colorectal | I-IV          | Down       | DFS               | 5.61         | 0.0009    |
| Schwander (84)     | 160             | Colorectal | I-III         | Up         | REC               | 5.21         | 0.0063    |
| Chatla (85)        | 158             | Colorectal | II-III        | Down       | OS                | 0.0242       |           |
| Sinicrope (89)     | 63              | Colorectal | I-II          | Up         | REC               | 0.0012       |           |
|                    |                 |            |               |            | OS                | 0.23         | 0.04      |
|                    |                 |            |               |            | RFS               | 0.17         | 0.03      |
| Krajewska (90)     | 154             | Colon      | II            | Up         | RFS               | 0.45         | 0.04      |
| Leahy (86)         | 106             | Colorectal | II            | Up         | OS                | 0.25         | 0.0009    |
| Ilyas (87)         | 102             | Colorectal | I-III         | Up         | OS                | 0.5          | 0.005     |
| Torsello (73)      | 66              | Colorectal | II            | Up         | REC               | 0.77         | 0.02      |
|                    | 58              | Colorectal | IV            | Down       | OS                | 3.02         | 0.015     |
|                    | (58)            | Colorectal | I-IV          | Up         | OS                |              |           |
|                    | (63)            | Colorectal | (30 years age) | Up         | OS                |              |           |
| Elkablawy (88)     | 52              | Colorectal | I-IV          | Up         | OS                |              | 0.016     |

Abbreviations: DFS (Disease Free survival), OS (Overall Survival), REC (Recurrence), RFS (Recurrence Free Survival), Up (Upregulation of marker expression), Down (Downregulation of marker expression).

Table 5: A list of 9 studies, identified by this review, describing a statistically significant, prognostic effect of Bcl-2 in colorectal cancer patients. For each maker, the important study characteristics are listed.

disease free, overall, or recurrence free survival. This is contradictory to what is assumed given the anti-apoptotic function of Bcl-2: upregulated Bcl-2 expression would be more likely to be a marker of a more aggressive tumor phenotype. The most plausible explanation for this paradoxical finding is the fact that Bcl-2 not only has an anti-apoptotic function, it can also exert a distinct negative influence on cell cycle progression which can eventually slow down tumor growth. This may explain the survival benefit for several patients with upregulated Bcl-2 expression (83-85;89). Whether the anti-cell cycle progression or the anti-apoptotic role of Bcl-2 predominates during tumorigenesis may depend on disease stage. In early carcinogenesis, the anti-apoptotic function of Bcl-2 plays a large role, causing genetic alterations to accumulate. In later stages, Bcl-2 functions more as a cell cycle progression inhibitor, lowering the rate of tumor proliferation. This hypothesis is supported by the inverse correlation between Bcl-2 and the percentage of cells in S-phase found by Buglioni et al. (83). The studies describing the prognostic relevance of Bcl-2 would therefore be more informative if disease stage would and the expression of the other family members were taken into account. This would provide us additional insight in the biologic function and effects on the apoptotic pathway of Bcl-2, which will tremendously improve the interpretation of the results.
CHAPTER 2

Inhibitors of apoptosis family proteins and the execution of apoptosis

The actual apoptotic cell death machinery, responsible for the execution of apoptosis and resulting in the morphologic features characteristic for apoptosis, consists of a very complex cascade of interacting proteins. The key components include the caspase proteins, as described above. At many levels regulation takes place to ensure appropriate functioning of the caspase machinery. The key regulators of the caspase cascade are the inhibitors of apoptosis proteins (IAPs) that exert their function through binding of activated caspases. So far, eight IAPs have been identified in mammals, the most well-known being livin, X-linked inhibitor of apoptosis (XIAP) and survivin (26;91;92). All IAP family proteins have one or several specific Baculoviral IAP repeats (BIRs). They require at least one BIR to exert their anti-apoptotic function. The function of the IAPs is also strictly regulated, by their own set of inhibitors such as Smac/Diablo and Omi/HtrA2 (26). Under normal circumstances, when apoptotic stimuli are present, cells release Smac/DIABLO from their mitochondria into the cytosol where the complex exerts its pro-apoptotic effect by interacting with the IAPs in order to release bound caspases into the cytosol (93). The most frequently studied IAP in our search results was survivin, likely because the role of survivin in apoptosis has been the subject of controversy over the last few of years. Of the 8 studies describing the prognostic effects of survivin, 4 demonstrated a statistically prognostic effect of survivin (35;90;94-99) (table 6). Initially it was thought that survivin and the other IAPs selectively bind active caspase-3/-7 and -9, promoting their degradation and thereby inhibiting apoptosis (100). Survivin, however, lacks the structural motif to bind to caspases and likely only inhibits activated caspase-9 with the help of XIAP (101-103). In contrast to other IAPs, surviving is undetectable in normal adult tissues, but abundantly expressed in transformed cell types and a variety of human cancers, such as cancers originating in the colon, stomach, pancreas, lung, prostate, and breast (104).

Although all four studies were able to show a significant relation between survivin expression and clinical outcome, the direction of this effect was not the same. When looking at these studies in detail it was noticed that they did not apply the same methods of analysis of the IHC results. This is of importance because survivin can be expressed in two cellular compartments: either in the cytoplasm or in the nucleus with different functions (98;105;106). In general, survivin is known to be involved in the regulation of cell viability as well as in the regulation of cell division. It is hypothesized that the nuclear subset is involved in controlling cell proliferation and the cytoplasmatic pool is more involved in regulating cell survival (107). Sarela et al. found a relationship between survivin expression and a shorter DFS when scoring mainly the cytoplasm for survivin positivity (94). Ponnelle et al. showed a positive influence of both cytoplasmatic and nuclear expression on survival in a very small patient population of only 46 patients. This only reached statistical significance for the cytoplasmic group (95). Fang et al. showed a negative effect of survivin expression on OS, disease recurrence, and the development of liver metastasis (108). The same was true for the study by Sprenger et al. in which pretreatment biopsies of rectal cancer patients were analyzed for their survivin
expression (99). In this study, low pre-treatment expression was related to a significantly better DFS. Unfortunately, neither of the groups elaborated on the specific location in the cell at which they scored survivin expression. The image of a tissue microarray (TMA) core that was immunohistochemically stained for survivin expression provided in the publication by Fang et al. suggests that the staining pattern was predominantly cytosplasmatic (108). In conclusion, it seems that localization of survivin expression is in fact of great importance as it is probably related to the protein function and hence should be taken into account in future studies. This may be applicable to all of the other IAP family members as none have been studied widely with standardized scoring methods in large series.

**DISCUSSION**

This review gives an overview of the literature published on IHC-based prognostic biomarkers related to the pathway of apoptosis in colorectal cancer between January 1998 and June 2011. Particularly, we discussed those markers that were proven to be of independent, statistically significant, prognostic value by placing them in the context of their function within the apoptotic pathway. Based on this biological background information, we then analyzed the conclusions drawn by the authors of the studies included to see whether their conclusions could provide valuable grounds to proceed investigating these markers for prognostic clinical application. The markers we discussed are all major regulatory players in this pathway such as p53, the Fas receptor and the DR4 with their respective ligands, the Bcl-2 protein family, and survivin. In general, we concluded that none qualified as a single prognostic biomarker for colorectal cancer patients, despite the fact that it has been well-established that the outcome of the pathway of apoptosis is of prognostic value (29-37;99). Based on the information derived from all of the
studies discussed, we postulate several explanations for this lack of sufficient clinical prognostic significance for individual markers of the apoptotic pathway. First, study characteristics of investigations of one specific biomarker varied widely. This sometimes provided a marker with prognostic significance, but only in a highly selected group of patients. For example, in the case of p53, some of the studies were able to reproduce the results of the review of Munro et al. (71), but only when a selected patient cohort was studied which consisted of patients with better survival rates after surgery, as was the case in the study by Lim et al (75). In this study, the prognostic value of p53 was only present in the stage II/III cohort when both adjuvant and non-adjuvant treated patients were included, which were probably the patients with such good outcome perspectives after surgery that adjuvant treatment was deemed unnecessary. The prognostic value disappeared when only the adjuvant-treated cases were analyzed. This makes the applicability of p53 as a general prognostic marker at time of diagnosis and treatment allocation questionable for the entire colorectal cancer patient population. Second, well-standardized IHC protocols were applied for none of these markers. Possibly even more importantly, there seemed to be no standardized methods for quantifying expression level or a specific location in the cell at which the expression of a marker should be evaluated. This may greatly influence the interpretation of the results of these studies, as for instance the specific location of expression in a cell might be directly related to its biological function and thereby to its effect on the outcome of the apoptotic pathway and patient prognosis. Caution should be taken in the method of quantification, particularly for FasR and survivin expression. In the case of the FasR expression, a high level of expression found in the cytoplasm but not on the cells membrane can indicate the presence of decoy receptors (56). This might be an indication that the so-called Fas-Counterattack hypothesis is indeed true, making it essential to evaluate the subcellular location of expression (55). In addition, in the case of survivin, staining location seemed to be of great importance as both nuclear and cytoplasmic expression showed a different relation with outcome in the studies reviewed (94;95;99;108). We concluded that location of expression might implicate different biological functions of the same protein. Third, we showed that the pathway of apoptosis is strictly regulated at several levels by both stimulatory and inhibitory proteins that highly interact with each other. Using only one marker to describe the outcome of these interactions, therefore, seems inappropriate. To complicate matters even more, the function of a protein might differ depending on progression of the process of tumorigenesis as was shown for Bcl-2 expression (83). Intervention of key proteins of apoptosis in other pathways makes cellular outcome unpredictable when using expression of single proteins as prognostic biomarkers.

Overall, we can conclude that studying outcome of the pathway of apoptosis, or deciding on a patient’s prognosis and treatment, using single markers seems inappropriate given the complexity of this pathway. We already highlighted the delicate balance that exists between expression and effects on apoptosis of the members of the Bcl-2 pathway and of the IAP’s and their inhibitors (78;83). To interpret the
effect of expression of single proteins without the knowledge of the expression status of any of the others involved seems inappropriate. Therefore, we would like to propose suggestions to improve the clinical applicability of these markers. Most importantly, we suggest that the apoptotic profile of a tumor should be determined rather than expression of single markers. This should include several markers that together represent the outcome of all regulatory thresholds within the pathway. An apoptotic profile would better represent the true function of the markers involved and provide insight on the outcome of the apoptotic pathway in individual tumors; thus, an apoptotic profile fulfills the need for prognostic biomarkers in colorectal cancer (22).

In the literature studied for this review, several authors already made an attempt to establish such a multi-marker apoptotic phenotype (59;60;83;99). However, in these studies, the selection of biomarkers was based on the markers that showed some prognostic relevance in their series as a single biomarker without any respect to the biology of the pathway. In addition, in most cases the markers used in these ‘multi-marker phenotypes’ all belonged to just one sub-regulatory unit of the pathway. For example, Van Geelen et al. and McLornan et al. both studied multiple markers with respect to the DRs, but did not include any of the more downstream regulator proteins (59;60). Furthermore, in many of the studies the statistical methods used to analyze the results of these multi-marker phenotypes lack power. A solution to this problem might be to approach the data as one would do in the case of gene expression array data by performing hierarchical clustering in order to develop a profile (109). Until then, the biomarkers that will eventually make up this apoptotic profile remain to be determined. In the meantime, we suggest that further studies focus on analyzing the clinical relevance of not only the outcome of (de) -regulation of the apoptotic pathway in colorectal cancer but also on the outcome of the (de) -regulation of the pathway of proliferation. Under normal circumstances a key factor in tissue homeostasis is the balance that exists between the level of cell death and the level of cell proliferation (110;111). Deregulation of either of these pathways can therefore cause disturbance of this balance, which may result in and maintain tumorigenesis. This hypothesis has been studied previously with success in a cohort of 100 colorectal cancer patients in which an AI:PI ratio was determined (112). This Apoptotic Index: Proliferation Index, based on M30 IHC for the level of apoptosis and Ki67 IHC for the proliferation index, was significantly to patient outcome. It remains to be seen if studies in larger patient populations will confirm these results.

In conclusion, to determine the prognostic relevance of biomarkers of the pathway of apoptosis in colorectal cancer using immunohistochemistry, multiple markers that together reflect the apoptotic status in individual tumors should be studied together. The introduction of such a multi-marker apoptotic phenotype or -profile into clinical practice demands standardization of technical assays and quantification methods. For future studies, therefore, we recommend to consider the full pathway when starting the exploratory phase towards the discovery of new biomarkers in colorectal cancer related to outcome of the apoptotic process.
Moreover, we recommend to apply hierarchical clustering-based statistical analysis and use knowledge of the biology of the pathway to identify promising markers. And furthermore, we recommend to even consider to take into account markers representing the pathway of proliferation when studying the prognostic effects of the apoptotic pathway in colorectal cancer. These measures will lead to multi-marker profiles that can then be validated in large retrospective studies and can ultimately be introduced into clinical practice.
(1) Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010 December 15;127(12):2893-917.
(2) Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011 March;61(2):69-90.
(3) Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003 January;53(1):5-26.
(4) Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. Cancer statistics, 2004. CA Cancer J Clin 2004 January;54(1):8-29.
(5) Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005 January;55(1):10-30.
(6) Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C et al. Cancer statistics, 2006. CA Cancer J Clin 2006 March;56(2):106-30.
(7) Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007 January;57(1):43-66.
(8) Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008 March;58(2):71-96.
(9) Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009 July;59(4):225-49.
(10) Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010 September;60(5):277-300.
(11) Greene FL, Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 2008 May;58(3):180-90.
(12) Benson AB, III, Schrag D, Somerfield MR, Cohen AM, Figueiredo AT, Flynn PJ et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004 August 15;22(16):3408-19.
(13) Chun YS, Vauthey JN. Extending the frontiers of resectability in advanced colorectal cancer. Eur J Surg Oncol 2007 December;33 Suppl 2:S52-S58.
(14) Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O’Connell MJ, Begovic M et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004 May 15;22(10):1785-96.
(15) Kahlenberg MS, Sullivan JM, Witmer DD, Petrelli NJ. Molecular prognostics in colorectal cancer. Surg Oncol 2003 November;12(3):173-86.
(16) Kozak KR, Moody JS. The impact of T and N stage on long-term survival of rectal cancer patients in the community. J Surg Oncol 2008 September 1;98(3):161-6.
(17) Poston GJ, Figueras J, Giulian F, Nuzzo G, Sobrero AF, Gigot JF et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008 October 10;26(29):4828-33.
(18) Roukos DH, Murray S, Briassoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007 March;6(3):308-12.
(19) Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, MacDonald JS et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006 November 20;24(33):5313-27.
(20) Duffy MJ, van DA, Haglund C, Hansson L, Holinski-Feder E, Klapdor R et al. Tumour markers in colorectal cancer: European
(21) Duffy MJ, van DA, Haglund C, Hansson L, Klapdor R, Lamerz R et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003 April;39(6):718-27.

(22) Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001 July;18(3):1054-61.

(23) Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 March 4;144(5):646-74.

(24) Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999 January 22;96(2):245-54.

(25) Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001 May 17;411(6835):342-8.

(26) Philchenkov A, Zavelevich M, Kroczak TJ, Los M. Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 2004 June;26(2):82-97.

(27) Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002 January 25;108(2):153-64.

(28) Adell GC, Zhang H, Evertsson S, Sun XF, Stal OH, Nordenskjold BA. Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy. Cancer 2001 May 15;91(10):1870-5.

(29) Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamium H, Collan Y et al. Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology 2003;64(4):435-42.

(30) de Bruin EC, van de Velde CJ, van de Pas S, Nagtegaal ID, van Krieken JH, Gosens MJ et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 2006 November 1;12(21):6432-6.

(31) Hilska M, Collan YU, VJ OL, Kossi J, Hirsimaki P, Laato M et al. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 2005 December;48(12):2197-208.

(32) Jonges LE, Nagelkerke JF, Ensink NG, van der Velde EA, Tollenaar RA, Fleuren GJ et al. Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest 2001 May;81(5):681-8.

(33) Langlois NE, Eremin O, Hey's SD. Apoptosis and proliferation in cancer: rationale and relevance. J R Coll Surg Edinb 2000 August;45(4):211-9.

(34) Marijnen CA, Nagtegaal ID, Mulder-Stapel AA, Schrier Pl, van de Velde CJ, van Krieken JH et al. High intrinsic apoptosis, but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys 2003 October 1;57(2):434-43.

(35) Rodel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002 August;178(8):426-35.

(36) Rupa JD, de Bruine AP, Gerbers AJ, Leers MP, Nap M, Kessels AG et al. Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low-turnover tumors with distinct
clinical outcome. Cancer 2003 May 15;97(10):2404-11.

(37) de HP, de Bruin EC, Klein-Kranenbarg E, Aalbers RI, Marijnen CA, Putter H et al. Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res 2007 October 1;13(19):5810-5.

(38) Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000 April 19;283(15):2008-12.

(39) Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006 August 7;25(34):4798-811.

(40) Winoto A. Cell death in the regulation of immune responses. Curr Opin Immunol 1997 June;9(3):365-70.

(41) Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003 November 24;22(53):8543-67.

(42) Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007 September;12(9):1543-68.

(43) Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000 April 10;256(1):58-66.

(44) Mahmoud Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res 2010 April 1;316(6):887-99.

(45) Fulda S, Debatin KM. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta 2004 December 10;1705(1):27-41.

(46) Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem 1997 July 11;272(28):17255-7.

(47) Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003 January;10(1):26-35.

(48) Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000 June;12(6):611-20.

(49) Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997 May 15;16(10):2794-804.

(50) Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 2002 September 2;21(17):4520-30.

(51) Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004 January 23;116(2):205-19.

(52) Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med 2010 February;31(1):93-112.

(53) Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomasselli KJ et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998 March 16;17(6):1675-87.

(54) Willis S, Day CL, Hinds MG, Huang DC. The Bcl-2-regulated apoptotic pathway. J Cell Sci 2003 October 15;116(Pt 20):4053-6.

(55) Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med 1996 December;2(12):1361-6.

(56) Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I
et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 2007 August;51(2):150-6.

(57) Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-RI is an independent prognostic parameter. Clin Cancer Res 2002 December;8(12):3734-40.

(58) Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehner T et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005 May;54(5):661-5.

(59) van Geelen CM, Westra JL, de Vries EG, Boersma-van EW, Zwart N, Hollema H et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006 November 1;24(31):4998-5004.

(60) McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010 July;16(13):3442-51.

(61) Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001 May 11;276(19):16484-90.

(62) Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 2005 September 1;65(17):7888-95.

(63) Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006 January;290(1):G129-G136.

(64) Zeestraaten EC, Van Hoesel AQ, Speetjens FM, Menon AG, Putter H, van de Velde CJ et al. FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer. Cancer Microenviron 2011 July 6.

(65) Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010 December;222(4):350-66.

(66) Krammer PH. CD95's deadly mission in the immune system. Nature 2000 October 12;407(6805):789-95.

(67) Mills AA. p53: link to the past, bridge to the future. Genes Dev 2005 September 15;19(18):2091-9.

(68) Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009 May 1;137(3):413-31.

(69) Bell HS, Dufes C, O’Prey J, Crighton D, Bergamaschi D, Lu X et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 2007 April;117(4):1008-18.

(70) Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991 June 6;351(6326):453-6.

(71) Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005 February 14;92(3):434-44.

(72) Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal
Review of IHC biomarkers

cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005 October 20;23(30):7518-28.

(73) Torsello A, Garufi C, Cosimelli M, Diodoro MG, Zeuli M, Vanni B et al. P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance. Eur J Cancer 2008 June;44(9):1217-22.

(74) Jurach MT, Meurer L, Moreira LF. Expression of the p53 protein and clinical and pathologic correlation in adenocarcinoma of the rectum. Arq Gastroenterol 2006 January;43(1):14-9.

(75) Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 2008 January;97(1):51-6.

(76) Noske A, Lipka S, Budczies J, Muller K, Loddenkemper C, Buhr HJ et al. Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer. Oncol Rep 2009 July;22(1):3-9.

(77) Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994 January;172(1):5-12.

(78) Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006 January;43(1):1-67.

(79) Saelens X, Festjens N, Vande WL, van GM, van LG, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004 April 12;23(16):2861-74.

(80) Nguyen M, Millar DG, Yong VW, Korsmeyer SJ, Shore GC. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993 December 5;268(34):25265-8.

(81) Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997 February 21;275(5303):1129-32.

(82) Bao Q, Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 2007 January;14(1):56-65.

(83) Buglioni S, D’Agnano I, Cosimelli M, Vasselli S, D’Angelo C, Tedesco M et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 1999 December 22;84(6):545-52.

(84) Schwandner O, Schiedeck TH, Bruch HP, Duchrow M, Windhoevel U, Broll R. Apoptosis in rectal cancer: prognostic significance in comparison with clinical histopathologic, and immunohistochemical variables. Dis Colon Rectum 2000 September;43(9):1227-36.

(85) Chatla C, Jhala NC, Katkooi VR, Alexander D, Meleth S, Grizzle WE et al. Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomark 2005;1(4-5):241-50.

(86) Leahy DT, Mulcahy HE, O’Donoghue DP, Parfrey NA. bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology 1999 October;35(4):360-7.

(87) Ilyas M, Hao XP, Wilkinson K, Tomlinson IP, Abbasi AM, Forbes A et al. Loss of Bcl-2 expression correlates with tumour...
recurrence in colorectal cancer. Gut 1998 September;43(3):383-7.

(88) Elkablawy MA, Maxwell P, Williamson K, Anderson N, Hamilton PW. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J Pathol 2001 August;194(4):436-43.

(89) Sinicrope FA, Hart J, Hsu HA, Lemoine M, Michelassi F, Stephens LC. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res 1999 July;5(7):1793-804.

(90) Krajewska M, Kim H, Kim C, Kang H, Welsh K, Matsuzawa S et al. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005 August 1;11(15):5451-61.

(91) Bergmann A, Yang AY, Srivastava M. Regulators of IAP function: coming to grips with the grim reaper. Curr Opin Cell Biol 2003 December;15(6):717-24.

(92) Deveraux QL, Stennicke HR, Salvesen GS, Reed JC. Endogenous inhibitors of caspases. J Clin Immunol 1999 November;19(6):388-98.

(93) Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, Melendez-Zaigla J. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res 2008;27:48.

(94) Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann Surg Oncol 2001 May;8(4):305-10.

(95) Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J et al. Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2005 August;131(8):504-10.

(96) Terzi C, Canda AE, Sagol O, Atila K, Sonmez D, Fuzun M et al. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 2008 January;23(1):37-45.

(97) Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998 November 15;58(22):5071-4.

(98) Li F, Yang J, Ramnath N, Javle MM, Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005 April 20;114(4):509-12.

(99) Sprenger T, Rodel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K et al. Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011 March 15;17(6):1623-31.

(100) Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003 November 24;22(53):8581-9.

(101) Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003 June 2;22(11):2729-40.

(102) Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004 August 13;279(33):34087-90.

(103) Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008 August 15;14(16):5000-5.
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997 August;3(8):917-21.

Li F. Survivin study: what is the next wave? J Cell Physiol 2003 October;197(1):8-29.

Fortugno P, Wall NR, Giodini A, O'Connor DS, Plessia J, Padgett KM et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002 February 1;115(Pt 3):575-85.

Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999 December 15;59(24):6097-102.

Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009 August;24(8):875-84.

Knosel T, Emde A, Schluns K, Chen Y, Jurchott K, Krause M et al. Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 2009 December 15;59(24):6097-102.

Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009 August;24(8):875-84.

Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995 May 1;55(9):1811-6.

Takano Y, Saegusa M, Ikenaga M, Mitomi H, Okayasu I. Apoptosis of colon cancer: comparison with Ki-67 proliferative activity and expression of p53. J Cancer Res Clin Oncol 1996;122(3):166-70.

Michael-Robinson JM, Reid LE, Purdie DM, Biemer-Huttmann AE, Walsh MD, Pandeya N et al. Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer. Clin Cancer Res 2001 August;7(8):2347-56.

Zlobec I, Terracciano L, Tornillo L, Gunthert U, Vuong T, Jass JR et al. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer. Gut 2008 October;57(10):1413-9.

Tornillo L, Lugli A, Zlobec I, Willi N, Glatz K, Lehmann F et al. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach. Am J Clin Pathol 2007 January;127(1):114-23.

Popat S, Chen Z, Zhao D, Pan H, Hearle N, Chandler I et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006 December;17(12):1810-7.

Watson NFS, Madjd Z, Scrimgeour D, Spendlove I, Ellis IO, Scholefield JH et al. Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. World Journal of Surgical Oncology 2005 July 19;3, 2005. Article Number: 47. Date of Publication: 19 Jul 2005.

Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clinical Cancer Research 2006;12(9):2738-44.

Zlobec I, Terracciano LM, Lugli A. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8(+) tumor-
infiltrating lymphocytes. Clinical Cancer Research 2008;14(12):3792-7.

(119) Peng JJ, Cai SJ, Lu HF, Cai GX, Lian P, Guan ZQ et al. Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers. World J Gastroenterol 2007 June 7;13(21):3009-15.

(120) Lan YT, Chang SC, Li AF, Lin TC, Chen WS, Jiang JK et al. p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis 2007 May;22(5):499-506.

(121) Zlobec I, Baker K, Terracciano LM, Lugli A. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res 2008 June 15;14(12):3798-806.

(122) Lam AKY, Ong K, Ho YH. hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features. International Journal of Colorectal Disease 2008;23(6):587-94.

(123) Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F et al. Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer 2007 May 7;96(9):1409-18.

(124) Benevolo M, Mottolese M, Piperno G, Sperduti I, Cione A, Sibillio L et al. HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. Am J Surg Pathol 2007 January;31(1):76-84.

(125) Fernandez-Cebrian JM, Nevado SM, Vorwald KP, Pardo de LM, Martin-Cavanna J, Pacheco MP et al. Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression? Clin Transl Oncol 2007 October;9(10):663-70.

(126) Koshiji M, Kumamoto K, Morimura K, Utsumi Y, Aizawa M, Hoshino M et al. Correlation of N-myc downstream-regulated gene 1 expression with clinical outcomes of colorectal cancer patients of different race/ethnicity. World J Gastroenterol 2007 May 28;13(20):2803-10.

(127) Broll R, Busch P, Duchsow M, Oevermann E, Schwandner O, Farke S et al. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. Int J Colorectal Dis 2005 March;20(2):94-102.

(128) Zhao DP, Ding XW, Peng JP, Zheng YX, Zhang SZ. Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B 2005 December;6(12):1163-9.

(129) Theodoropoulos GE, Lazaris AC, Theodoropoulos VE, Papatheodosiou K, Gazouli M, Bramis J et al. Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer. Int J Colorectal Dis 2006 April;21(3):248-57.

(130) Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007 August 1;68(5):1455-61.

(131) Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006 February 15;12(4):1184-91.

(132) Lin LC, Lee HH, Hwang WS, Li CF, Huang CT, Que J et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 2006 December;15(4):211-6.
(133) Terzi C, Canda AE, Sagol O, Atila K, Sonmez D, Fuzun M et al. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. International Journal of Colorectal Disease 2008;23(1):37-45.

(134) Tzouvala M, Lazaris AC, Papaethodoridis GV, Kouvidou C, Papathomas TG, Kavantzas N et al. Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival. Dig Dis Sci 2008 February;53(2):451-60.

(135) Lebe B, Sarioglu S, Sokmen S, Ellidokuz H, Fuzun M, Kupelioglu A. The clinical significance of p53, p21, and p27 expressions in rectal carcinoma. Appl Immunohistochem Mol Morphol 2005 March;13(1):38-44.

(136) King-Yin LA, Ong K, Ho YH. Colorectal mucinous adenocarcinoma: the clinicopathologic features and significance of p16 and p53 expression. Dis Colon Rectum 2006 September;49(9):1275-83.

(137) Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004 May 1;22(9):1572-82.

(138) Fernebro E, Bendahl PO, Dictor M, Persson A, Ferno M, Nilbert M. Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer 2004 October 10;111(6):921-8.

(139) Manne U, Weiss HL, Grizzle WE. Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int J Cancer 2000 September 20;89(5):423-30.

(140) Schwandner O, Schiedeck TH, Bruch HP, Duchrow M, Windhoevel U, Broll R. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 2000 February;36(3):348-56.

(141) Kouraklis G, Kakisis J, Theoharis S, Tzonou A, Glinavou A, Raftopoulos J et al. Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer. Dig Dis Sci 2003 December;48(12):2284-9.

(142) Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulas V, Gatter KC et al. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999 October 15;86(8):1421-30.

(143) Rosati G, Chiachio R, Reggiardo G, De SD, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 2004 September;25(5-6):258-63.

(144) Hoos A, Nissan A, Stojadinovic A, Shia J, Hedvat CV, Leung DH et al. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 2002 December;8(12):3841-9.

(145) Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001 April;44(4):523-33.

(146) Bukholm IK, Nesland JM. Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human
colon carcinomas. Virchows Arch 2000 March;436(3):224-8.

(147) Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J et al. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer 2001 March 2;84(5):651-8.

(148) Meterissian SH, Kontogiannnea M, Al-Sowaidi M, Linjawi A, Halwani F, Jamison B et al. Bcl-2 is a useful prognostic marker in Dukes’ B colon cancer. Ann Surg Oncol 2001 July;8(6):533-7.

(149) Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, Garcia-Aguilar J. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000 April;43(4):451-9.

(150) Ishijima N, Miki C, Ishida T, Kinoshita T, Suzuki H. The immunohistochemical expression of BCL-2 oncoprotein in colorectal adenocarcinoma. Surg Today 1999;29(7):682-4.

(151) Sun N, Meng Q, Tian A. Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. Am J Surg 2010 September;200(3):341-5.

(152) Zlobec I, Minoo P, Baker K, Haegert D, Khetani K, Tornillo L et al. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer 2007 April;43(6):1101-7.

(153) Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR et al. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008 February 1;112(3):495-502.

(154) Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX et al. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol 2007 December;14(12):3453-9.

(155) Strater J, Herter I, Merkel G, Hinz U, Weitz J, Moller P. Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer 2010 August 15;127(4):873-80.

(156) Nehls O, Okech T, Hsieh CJ, Sarbia M, Borchard F, Gruenagel HH et al. Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. Int J Radiat Oncol Biol Phys 2005 January 1;61(1):85-91.

(157) Schelwies K, Sturm I, Grabowski P, Scherubl H, Schindler I, Hermann S et al. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer 2002 June 1;99(4):589-96.

(158) Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003 September 15;21(18):3391-401.

(159) Cascini S, Graziano F, Catalano V, Staccioli MP, Rossi MC, Baldelli AM et al. An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. Br J Cancer 2002 March 4;86(5):744-9.

(160) Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE et al. Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res 2008 July 1;14(13):4128-33.
(161) Sinicrope FA, Rego RL, Okumura K, Foster NR, O’Connell MJ, Sargent DJ et al. Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res 2008 September 15;14(18):5810-8.

(162) Ponnelle T, Chapusot C, Martin L, Bonithon-Kopp C, Bouvier AM, Plenchette S et al. Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: relationships with clinicopathological features and prognosis. Pathol Res Pract 2003;199(11):723-31.

(163) Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986 November 1;2(8514):996-9.

(164) De Oliveira LF, De Oliveira CH, Barrezueta LF, Fujiyama Oshima CT, Silva JA, Jr., Gomes TS et al. Immunoeexpression of inhibitors of apoptosis proteins and their antagonist SMAC/DIABLO in colorectal carcinoma: correlation with apoptotic index, cellular proliferation and prognosis. Oncol Rep 2009 August;22(2):295-303.

(165) Endo K, Kohnoe S, Watanabe A, Tashiro H, Sakata H, Morita M et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep 2009 February;21(2):351-5.
# SUPPLEMENTARY DATA

List of abbreviations (in order of appearance)

| Abbreviation | Definition |
|--------------|------------|
| IHC          | Immunohistochemistry |
| CRC          | Colorectal Cancer |
| ASCO         | American Association of Clinical Oncology |
| EGTM         | European Group on Tumor Markers |
| Bcl-2        | B-cell Lymphoma 2 |
| P53          | Protein 53 |
| TRAILR1      | Tumor necrosis factor Related Apoptosis Inducing Ligand Receptor 1 |
| UICC         | International Union Against Cancer |
| TNM          | Tissue Node Metastasis |
| ASCO-TEMP    | American Association of Clinical Oncology Tumor Markers Expert Panel |
| DNA          | Deoxyribonucleic Acid |
| UV           | Ultraviolet |
| IAP          | Inhibitor of Apoptosis Protein |
| DR           | Death Receptor |
| FasR         | Fas Receptor |
| TRAILR2/R3/R4| TRAIL Receptor 2/3/4 (see TRAILR1) |
| FasL         | Fas Ligand |
| c-Flip       | Cellular FADD Like Interleukin 1 beta-converting Enzyme Inhibitory Protein (see FADD) |
| TNFR         | Tumor Necrosis Factor Receptor |
| DD           | Death Domain |
| FADD         | Fas-Associated Death Domain |
| DISC         | Death Inducing Signalling Complexes |
| DcR1/2       | Decoy Receptor 1/2 |
| MHC          | Major Histocompatibility Complex |
| OS           | Overall Survival |
| DFS          | Disease Free Survival |
| NF-κB        | Nuclear Factor kappa-light-chain-enhancer of activated B cells |
| CD8          | Cluster of Differentiation 8 |
| CD95         | Cluster of Differentiation 95 |
| T cell       | Thymus cell |
| CD95L        | CD 95 ligand (see CD 95) |
| Bcl-2 XL     | Bcl-2 Extra Large (see Bcl-2) |
| MOM          | Mitochondrial Outer Membrane |
| TM           | Transmembrane |
| BAX          | Bcl-2 Associated X protein (see Bcl-2) |
| BAD          | Bcl-2 Associated Death Promoter (see Bcl-2) |
| Bim          | Bcl-2 like interacting mediator of cell death (see Bcl-22) |
| Bid          | BH3 interacting domain death agonist (see BH3) |
Puma  
TUCAN  
CARD  
BH3  
Apaf-1  
S-phase  
XIAP  
BIR  
SMAC  
DIABLO  
HtrA2  
TMA  
N  
Bag1  
REC  
RFS 

P53 upregulated modulator of apoptosis  
Tumor-upregulated CARD containing antagonist of caspase 9 (see CARD)  
Caspase Recruitment Domain  
Bcl-2 Homology 3 (see Bcl-2)  
Apoptosis-Activating factor 1  
Synthesis phase  
X-linked IAP (see IAP)  
Baculovirus IAP Repeat (see IAP)  
Second Mitochondria-Derived Activator of Caspases  
Direct IAP Binding protein with Low pl. (see IAP)  
High temperature requirement protein A2  
Tissue Micro Array  
number of patients in study population  
Bcl-2 associated Athanogene 1  
Recurrence  
Recurrence Free survival